Skip to content
10 08, 2018

Replace dolutegravir (Tivicay) with raltegravir (Isentress) for post-exposure prophylaxis

2018-08-10T04:08:00+00:00

raltegravirPost-exposure prophylaxis (PEP) of patients who may have been exposed to HIV includes a combination HIV nucleoside analog reverse transcriptase inhibitor emtricitabine/tenofovir (Truvada) plus an integrase inhibitor. The CDC initially recommended the integrase inhibitor dolutegravir (Tivicay). However on May 18, 2018, the CDC placed an alert about the neural tube defect risk with dolutegravir.1 How does this change our ED practice?
(more…)

11 06, 2018

The Myth of Vasopressors and Ischemia

2018-06-11T08:02:01+00:00

Despite the widespread clinical use, and their well-documented life-saving properties, vasopressors are often maligned, accused of causing ischemia to fingers, toes, mesentery, kidneys, and so forth. Not only is the evidence that this happens poor, but, a fear of this dreaded complication can unwarrantedly lead good clinicians to limit or withhold potentially life- and organ-saving medications. This article showcases the importance of end-organ perfusion and explains how vasopressors may in fact be one of the most important therapies in an emergency physician’s armamentarium.
(more…)

8 06, 2018

Trigger Point Injection for Musculoskeletal Pain in the ED

2018-06-07T20:29:26+00:00

Musculoskeletal pain is a common ED presentation and emergency providers can often manage it with NSAIDs alone.1 On the other hand, when patients present with small localized areas of intense muscle spasm called trigger points, NSAIDs won’t cut it. A trigger point injection (TPI), however, is a safe and easy way to treat the underlying cause of trigger point pain, and requires only basic equipment already available in most the EDs.

(more…)

30 05, 2018

Treating Opioid Withdrawal in the ED with Buprenorphine: A Bridge to Recovery

buprenorphineThe Emergency Department (ED) is the frontline of the opioid crisis, treating patients with opioid-related infections, opioid withdrawal, and overdose. These encounters can be difficult or even downright confrontational. But that does not have to be the case! With the use of buprenorphine, we can “flip the script” for these encounters, encouraging patient-provider collaboration in the treatment of opioid addiction as medical disease.

(more…)

13 05, 2018

Ketamine for Severe Ethanol Withdrawal: A New Hope?

2018-05-15T04:39:17+00:00

Ketamine for severe ethanol withdrawalEthanol withdrawal is a complex disease state. Two of the main players are GABA (an inhibitory neurotransmitter) and glutamate (an excitatory transmitter that can act on NMDA receptors). Simplistically, chronic ethanol use leads to a down-regulation of GABA receptors and an up-regulation in glutaminergic receptors, such as NMDA. When ethanol is abruptly discontinued, we are left with a largely excitatory state with less ability for GABA-mediated inhibition and more capacity for NMDA/glutamate-mediated excitation. While much of the treatment of severe ethanol withdrawal is focused on GABA, there are agents, such as phenobarbital and propofol, that can suppress the glutaminergic response. Ketamine seems like it should confer benefit, as well, due to its NMDA antagonist properties. Until recently there was only one clinical study using ketamine for severe ethanol withdrawal.1 Now there are three.2,3

(more…)

9 04, 2018

ACMT Toxicology Visual Pearls: Spider Bite

2018-04-09T07:05:30+00:00

A patient presents to the ED for management of a spider bite. Which of the following statements is correct regarding a bite from the spider pictured?

  1. Laboratory studies can be helpful in management and predicting outcome.
  2. Antibiotics are recommended.
  3. The venom is cytotoxic and can cause red blood cell hemolysis.
  4. The venom is more potent on a volume-per-volume basis than the venom of a pit viper.

(more…)